Ibnsina Pharma (EGX:ISPH)
Egypt · Delayed Price · Currency is EGP 10.95
-0.12 (-1.08%)
At close: Feb 2, 2026
Ibnsina Pharma Cash Flow Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 867.89 | 614.56 | 213.66 | 172.58 | 314.73 | 224.66 |
Depreciation & Amortization | 290.79 | 242.2 | 184.22 | 182.53 | 175.34 | 129.21 |
Other Amortization | 26.76 | 23.53 | 6.57 | 5.64 | 2.75 | 1.91 |
Loss (Gain) From Sale of Assets | -52.86 | -2.95 | -1.39 | -1.21 | -4.25 | -1.94 |
Loss (Gain) on Equity Investments | -1.85 | -1.56 | 1.13 | - | - | - |
Provision & Write-off of Bad Debts | 288.1 | 215.37 | 83.85 | 65.53 | -45.13 | 24.34 |
Other Operating Activities | 380.47 | 407.75 | 173.02 | -41.75 | 88.58 | -13.32 |
Change in Accounts Receivable | -6,527 | -6,643 | -4,068 | -85.2 | -1,284 | -410.14 |
Change in Inventory | -2,302 | -3,578 | -671.73 | -400.14 | -194.15 | -348.14 |
Change in Accounts Payable | 4,655 | 8,151 | 4,386 | 558.68 | 697.3 | 751.2 |
Change in Other Net Operating Assets | -484.8 | -356.43 | -181.75 | -94.79 | -91.78 | -105.91 |
Operating Cash Flow | -2,859 | -926.58 | 125.81 | 361.88 | -340.43 | 251.87 |
Operating Cash Flow Growth | - | - | -65.23% | - | - | - |
Capital Expenditures | -428.9 | -260.05 | -354.04 | -798.46 | -147.53 | -230.13 |
Sale of Property, Plant & Equipment | 179.05 | 23.4 | 82.45 | 50.45 | 16.01 | 2.42 |
Sale (Purchase) of Intangibles | -39.36 | -22.89 | -8.23 | -26.18 | -11.15 | -0.32 |
Other Investing Activities | - | - | - | -601.86 | - | - |
Investing Cash Flow | -289.21 | -259.54 | -279.82 | -1,376 | -142.67 | -228.03 |
Short-Term Debt Issued | - | 1,214 | 875.52 | 721.63 | 960.4 | 330.99 |
Long-Term Debt Issued | - | 577.29 | 362.57 | 712.39 | - | - |
Total Debt Issued | 4,203 | 1,791 | 1,238 | 1,434 | 960.4 | 330.99 |
Long-Term Debt Repaid | - | -874.29 | -471.63 | -21.53 | -250.65 | -120.39 |
Total Debt Repaid | -648.79 | -874.29 | -471.63 | -21.53 | -250.65 | -120.39 |
Net Debt Issued (Repaid) | 3,554 | 916.87 | 766.46 | 1,412 | 709.75 | 210.6 |
Issuance of Common Stock | - | - | - | 0.49 | - | - |
Repurchase of Common Stock | - | - | - | -185.74 | -14.4 | - |
Common Dividends Paid | -39.76 | -25.62 | -22.94 | -140.4 | -14.59 | -82.02 |
Financing Cash Flow | 3,514 | 891.25 | 743.52 | 1,087 | 680.77 | 128.58 |
Net Cash Flow | 365.48 | -294.87 | 589.52 | 72.67 | 197.66 | 152.42 |
Free Cash Flow | -3,288 | -1,187 | -228.23 | -436.58 | -487.96 | 21.75 |
Free Cash Flow Margin | -4.52% | -2.13% | -0.67% | -1.96% | -2.25% | 0.12% |
Free Cash Flow Per Share | -3.26 | -1.18 | -0.23 | -0.43 | -0.38 | 0.02 |
Cash Interest Paid | 2,071 | 1,375 | 929.98 | 481.52 | 281.54 | 250.34 |
Cash Income Tax Paid | 55.38 | - | - | - | 76.32 | 85.85 |
Levered Free Cash Flow | -7,584 | -7,044 | -2,724 | -1,495 | -617.13 | -1,068 |
Unlevered Free Cash Flow | -6,029 | -5,990 | -2,071 | -1,197 | -439.52 | -908.37 |
Change in Working Capital | -4,659 | -2,425 | -535.24 | -21.45 | -872.44 | -112.99 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.